1. Home
  2. VPG vs ADCT Comparison

VPG vs ADCT Comparison

Compare VPG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VPG

Vishay Precision Group Inc.

HOLD

Current Price

$44.78

Market Cap

552.5M

Sector

Technology

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.79

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VPG
ADCT
Founded
2009
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
552.5M
484.4M
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
VPG
ADCT
Price
$44.78
$3.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$53.50
$7.75
AVG Volume (30 Days)
209.6K
759.1K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.86
EPS
0.40
N/A
Revenue
$307,202,000.00
$81,357,000.00
Revenue This Year
$7.21
N/A
Revenue Next Year
$6.92
$66.49
P/E Ratio
$111.93
N/A
Revenue Growth
0.22
14.85
52 Week Low
$18.57
$1.05
52 Week High
$56.25
$4.98

Technical Indicators

Market Signals
Indicator
VPG
ADCT
Relative Strength Index (RSI) 52.95 43.30
Support Level $44.01 $3.65
Resistance Level $48.61 $3.87
Average True Range (ATR) 2.64 0.21
MACD 0.36 -0.04
Stochastic Oscillator 67.19 29.73

Price Performance

Historical Comparison
VPG
ADCT

About VPG Vishay Precision Group Inc.

Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: